Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$36.91 USD

36.91
4,316,313

-1.06 (-2.79%)

Updated Oct 1, 2024 04:00 PM ET

Pre-Market: $36.91 0.00 (0.00%) 8:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Stryker Gains From Flagship Mako and Broad Product Spectrum

Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.

Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test

The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.

Haemonetics Grows on Strong Plasma, Hemostasis Management

Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.

Here's Why You Should Hold on to Wright Medical (WMGI) Stock

Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

Fresenius Medical Launches 4008A Dialysis Machine in China

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

Align Technology Inks Distribution Deal With Zimmer Biomet

This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.

PRA Health Simplifies Treatment Decisions With Metys Launch

PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.

Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ

Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.

Here's Why You Should Retain Pacific Biosciences For Now

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line

Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.

Abbott Receives European Nod for Pediatric Heart Devices

Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.

Intersect ENT Rides on Innovation Amid Pricing Concerns

The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.

HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set

HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.

Here's Why You Should Retain OPKO Health (OPK) Stock For Now

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.

Varian's ProBeam Now Available in Multi-Room Configuration

Shandong Cancer Hospital in China selects Varian (VAR) to equip its new research center with the ProBeam Proton Therapy system.

Medtronic Collaborates With Novo Nordisk for Diabetes Care

This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.

Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International

Zacks.com featured highlights include: Medtronic, Symantec, Target, Popular and Baxter International

Here's Why You Should Retain Patterson Companies (PDCO) Now

Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.

Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement

With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.